Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial
Por:
Ciruelos E, Villagrasa P, Pascual T, Oliveira M, Pernas S, Pare L, Escriva-de-Romani S, Manso L, Adamo B, Martinez E, Cortes J, Vazquez S, Perello A, Garau I, Mele M, Martinez N, Montano A, Bermejo B, Morales S, Echarri M, Vega E, Gonzalez-Farre B, Martinez D, Galvan P, Canes J, Nuciforo P, Gonzalez X, Prat A
Publicada:
15 nov 2020
Resumen:
Purpose: To assess palbociclib in combination with trastuzumab with or without endocrine therapy in patients with HER2-positive advanced breast cancer.
Patients and Methods: PATRICIA is a prospective, open-label, multicenter phase II trial. Patients had received 2-4 prior lines of anti-HER2-based regimens. Treatment consisted of palbociclib 200 mg daily for 2 weeks and 1 week off plus trastuzumab. The study was based on a Simon two-stage design comprising three cohorts: estrogen receptor (ER)-negative (cohort A), ER-positive (cohort B1), and ER-positive with letrozole (cohort B2). ER-positive patients were randomized to cohorts B1 or B2. Primary endpoint was progression-free survival rate at 6 months (PFS6). Secondary objectives included safety and evaluation of the PAM50 intrinsic subtypes.
Results: Seventy-one patients were recruited (n = 15 in cohort A and 28 in each cohort B). The PFS6 rate in cohorts A, B1, and B2 was 33.3% (5/15), 42.8% (12/28), and 46.4% (13/28), respectively. Regarding safety, grade 1-2 and 3-4 toxicities occurred in 97.7% and 84.4% of patients, respectively. The most common grade 3-4 toxicities were neutropenia (66.4%) and thrombocytopenia ( 11.3%). Regarding PAM50, 59 (83.1%) tumors were profiled. Luminal disease defined by PAM50 was found independently associated with longer PFS compared with non-luminal disease (10.6 vs. 4.2 months median PFS; adjusted hazard ratio = 0.40; P = 0.003).
Conclusions: Palbociclib in combination with trastuzumab is safe and exhibits promising survival outcomes in trastuzumab pretreated ER-positive/HER2-positive advanced breast cancer with a PAM50 Luminal A or B subtype. The enrollment was stopped prematurely, and a new randomized cohort was opened in this population.
Filiaciones:
Ciruelos E:
Hosp Univ 12 Octubre, Ave Cordoba S-N, Madrid 28041, Spain
Ctr Integral Oncol Clara Campal HM CIOCC, Madrid, Spain
SOLTI Breast Canc Res Grp, Barcelona, Spain
Villagrasa P:
SOLTI Breast Canc Res Grp, Barcelona, Spain
Pascual T:
SOLTI Breast Canc Res Grp, Barcelona, Spain
Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain
Hosp Clin Barcelona, Barcelona, Spain
Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA
Oliveira M:
SOLTI Breast Canc Res Grp, Barcelona, Spain
Vall dHebron Univ Hosp, Barcelona, Spain
Vall dHebron Inst Oncol VHIO, Barcelona, Spain
Pernas S:
SOLTI Breast Canc Res Grp, Barcelona, Spain
Inst Catala Oncol, Lhospitalet De Llobregat, Spain
Pare L:
SOLTI Breast Canc Res Grp, Barcelona, Spain
Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain
Escriva-de-Romani S:
Vall dHebron Univ Hosp, Barcelona, Spain
Manso L:
Hosp Univ 12 Octubre, Ave Cordoba S-N, Madrid 28041, Spain
Adamo B:
Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain
Hosp Clin Barcelona, Barcelona, Spain
Martinez E:
Consorcio Hosp Prov Castellon, Castellon de La Plana, Spain
Cortes J:
IOB Inst Oncol, Quiron Grp, Madrid, Spain
IOB Inst Oncol, Quiron Grp, Barcelona, Spain
Vazquez S:
Inst Catala Oncol, Lhospitalet De Llobregat, Spain
Perello A:
Hosp Univ Son Espases, Palma De Mallorca, Spain
Garau I:
Hosp Son Llatzer, Palma De Mallorca, Spain
Mele M:
Hosp Univ St Joan de Reus, Reus, Spain
Martinez N:
Hosp Univ Ramon y Cajal, Madrid, Spain
Montano A:
Hosp Univ Virgen del Rocio, Seville, Spain
Bermejo B:
Hosp Clin Univ Valencia, Valencia, Spain
Morales S:
Hosp Univ Arnau de Vilanova Lleida, Lleida, Spain
Echarri M:
Hosp Univ Severo Ochoa, Madrid, Spain
Vega E:
Ctr Integral Oncol Clara Campal HM CIOCC, Madrid, Spain
Gonzalez-Farre B:
Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain
Hosp Clin Barcelona, Barcelona, Spain
Martinez D:
Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain
Galvan P:
Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain
Canes J:
SOLTI Breast Canc Res Grp, Barcelona, Spain
Nuciforo P:
Vall dHebron Univ Hosp, Barcelona, Spain
Vall dHebron Inst Oncol VHIO, Barcelona, Spain
Gonzalez X:
SOLTI Breast Canc Res Grp, Barcelona, Spain
Inst Oncol Dr Rosell, Barcelona, Spain
Hosp Gen Cataluna, Sant Cugat Del Valles, Spain
Prat A:
SOLTI Breast Canc Res Grp, Barcelona, Spain
Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain
Hosp Clin Barcelona, Barcelona, Spain
|